The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Sep. 28, 2015
Applicant:

Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts, Heidelberg, DE;

Inventors:

Peter Altevogt, Neckargemünd, DE;

Sandra Lüttgau, Schongau, DE;

Gerhard Moldenhauer, Bad Arolsen, DE;

John Hazin, Heidelberg, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 31/337 (2006.01); A61K 31/277 (2006.01); A61K 31/365 (2006.01); A61K 31/407 (2006.01); A61K 31/513 (2006.01); A61K 31/535 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 33/24 (2019.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61K 38/15 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 31/277 (2013.01); A61K 31/337 (2013.01); A61K 31/365 (2013.01); A61K 31/407 (2013.01); A61K 31/513 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 33/24 (2013.01); A61K 38/15 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.


Find Patent Forward Citations

Loading…